Bearing Point Capital LLC Acquires 2,568 Shares of Stryker Corporation $SYK

Bearing Point Capital LLC raised its holdings in Stryker Corporation (NYSE:SYK) by 12.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 23,180 shares of the medical technology company’s stock after buying an additional 2,568 shares during the quarter. Stryker makes up about 1.3% of Bearing Point Capital LLC’s holdings, making the stock its 27th largest position. Bearing Point Capital LLC’s holdings in Stryker were worth $8,147,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter valued at $27,000. Strive Asset Management LLC bought a new position in shares of Stryker in the third quarter valued at $30,000. CGC Financial Services LLC bought a new position in shares of Stryker in the fourth quarter valued at $29,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker in the third quarter valued at $34,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $305.73 on Friday. The firm has a 50-day moving average of $321.82 and a 200-day moving average of $348.15. The company has a market cap of $117.21 billion, a P/E ratio of 35.39, a P/E/G ratio of 1.92 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analysts Set New Price Targets

A number of research firms have weighed in on SYK. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Citigroup lowered their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Finally, Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.